Each is supported by domain-tuned routing, a panel matched to the field, and a body of real-world verifications you can audit.
Limitation of liability missing fraud carve-outs. IP clauses with ambiguous "work product" language. Termination clauses inconsistent with payment schedules. BRIDGE catches what tired-eyes do at 11pm.
The Service Provider's liability shall be limited to actual, directdirectdamages not exceeding the fees paid by Customer in the twelve (12) months immediately preceding the event giving rise to the claim, except in cases of fraud, gross negligence, willful misconduct, or breach of confidentiality obligations.
F-01 · Missing fraud carve-out (CA Civ. Code §1668). F-02 · "Direct damages" ambiguous — qualified with "actual, direct".
Fraud, willful misconduct, personal injury. Most LoL clauses miss at least one — and case law voids the rest.
"Reasonable", "direct", "promptly" — terms that don't survive litigation. BRIDGE proposes precise alternatives with citation.
Payment terms in §6 don't match termination in §9. Indemnification scope contradicts insurance schedule. Easy to miss, expensive when missed.
BRIDGE runs every diff through a panel tuned for security, correctness, and behavioral edge cases. The bug that took down your last service? It's the kind we'd catch in 3.9 seconds.
def authenticate(token: str) -> User | None:
try:
payload = jwt.decode(token, SECRET, algorithms=["HS256"], options={"require": ["exp"]})
except jwt.InvalidTokenError:
return None
return User(**db.users.find_one({"id": payload["sub"]}))
F-01 · Unhandled jwt.InvalidTokenError. F-02 · No expiry enforcement. F-03 · Timing-safe compare missing on /login (split — style debate).
Timing attacks, token validation gaps, prompt-injection vectors. Cross-checked against current CVE feed.
The 5pm Friday bugs. Models trace likely runtime states, not just compile-time.
N+1 queries, unbounded loops, missing error boundaries. Logs that don't say enough to debug from.
Insurance claims, scientific manuscripts, market sizing memos, regulatory filings. Anywhere a specific number or named source matters, BRIDGE checks if the claim survives challenge.
The new XR-7 imaging protocol reduces patient radiation exposure by 47% [citation needed] compared to standard CT while maintaining diagnostic accuracy above 92%96%. In our cohort of 1,200 patients (824 unique imaging episodes), no false-negative diagnoses recorded over 18 months [follow-up rate not specified].
Citation missing. Accuracy over-stated (92.3% in cited data). Cohort/episode conflation. Follow-up rate unspecified.
The "47% reduction" that no model can trace. Most common defect in scientific and marketing copy.
"Accuracy above 96%" when the cited paper reports 92%. BRIDGE reconciles the claim to source.
Sample size without unique-N. Zero false-negatives without follow-up rate. Sounds rigorous; isn't.
Pipeline projections without bottom-up validation. NRR assumptions that mask variance. "Break-even" without specifying operating vs cash. The kind of language that survives until it reaches a board meeting.
Q4 projection: 38% YoY growth driven by enterprise expansion. Assumes 5 net-new logos at $250K ACV (pipeline · 60% close rate), 110% NRR (±8 pp historical variance), stable 28-day cycle. Sensitivity: 10% conversion drop cuts FY revenue $4.2M and pushes break-even into Q2 [operating, not cashflow].
Pipeline source added. NRR variance disclosed. Break-even definition split — flagged for author choice.
"5 logos at $250K ACV" — assumed, not sourced. BRIDGE flags and asks for the actual pipeline opps.
NRR shown as a single number when the trailing-quarter range was 103–115. Variance disclosure forced.
"Break-even" — operating or cash? "Growth" — gross or net? Forced specificity.
HEART scores missing from chest-pain notes. Serial troponin intervals unspecified. Aspirin given without contraindication review charted. BRIDGE catches the omissions that turn into malpractice exposure — and the protocol misses that cost lives.
Patient: 3-day intermittent L-sided chest pain, radiates to jaw, worse w/ exertion. Vitals stable. ECG: non-specific ST changes. Troponin pending. Plan: admit, serial troponins q3h x3, cardiology consult; ASA 325mg given (no contraindications noted). HEART score: 5 (moderate risk). Pre-test risk stratification before discharge.
HEART score documented. Serial troponin interval specified. ASA contraindication review split (defensive charting).
HEART, NIHSS, qSOFA, CURB-65. When protocol mandates a score, BRIDGE checks it's there with values.
q3h x3, q6h x2, etc. Standard protocols expect interval; nursing defaults to longer when omitted.
ASA, anticoag, contrast. "Allergy reviewed", "no contraindications" — phrases that close a case.
Vendor onboarding policies missing Art. 35 DPIA requirements. Internal AI use policies aligned to outdated framework versions. BRIDGE knows the current versions of every major framework and flags the gaps that audit comes for.
All third-party AI systems processing customer data must be reviewed annually with a DPIA per GDPR Article 35 and approved by the CISO with current SOC 2 Type II attestation on file. Approved systems listed in the enterprise AI registry maintained by InfoSec.
F-01 · Missing DPIA requirement (GDPR Art. 35). F-02 · Current SOC 2 Type II not mandated.
GDPR Art. 35 DPIA for high-risk AI. SOX 404(b) for sub-issuers. HIPAA §164.308 admin safeguards. The ones policies skip.
NIST 800-53 Rev 4 when Rev 5 is current. ISO 27001:2013 when :2022 supersedes. Auto-flagged.
Policies that name a control but not the evidence trail. BRIDGE proposes the minimum artifact set.